Agreements reveal some surprises

The MA agreement has delivered outcomes on biosimilars, second brands and establishes a potential relationship between post-market reviews and statutory price reductions. GBMA has secured an extension to its existing agreement and a grant from government to conduct biosimilar education targeting healthcare professionals. …